Michael Ryskin
Stock Analyst at B of A Securities
(1.39)
# 3,465
Out of 4,963 analysts
37
Total ratings
47.83%
Success rate
-2.67%
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $68 → $70 | $73.23 | -4.41% | 6 | Jun 25, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $535 → $475 | $640.86 | -25.88% | 3 | Apr 21, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Buy | $9 → $8 | $2.33 | +243.35% | 3 | Mar 3, 2025 | |
| ALGN Align Technology | Maintains: Underperform | $200 → $206 | $141.98 | +45.09% | 6 | Dec 13, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $63.50 | -37.01% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $3.91 | +142.97% | 1 | Jun 25, 2024 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $10.99 | +118.48% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $13.19 | +81.96% | 2 | Jul 31, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $155.37 | +15.85% | 7 | Nov 4, 2022 | |
| RXRX Recursion Pharmaceuticals | Downgrades: Neutral | n/a | $4.89 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $19.79 | +162.76% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $2.55 | +292.16% | 2 | Nov 10, 2021 |
Tempus AI
Jun 25, 2025
Maintains: Neutral
Price Target: $68 → $70
Current: $73.23
Upside: -4.41%
IDEXX Laboratories
Apr 21, 2025
Maintains: Neutral
Price Target: $535 → $475
Current: $640.86
Upside: -25.88%
Maravai LifeSciences Holdings
Mar 3, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.33
Upside: +243.35%
Align Technology
Dec 13, 2024
Maintains: Underperform
Price Target: $200 → $206
Current: $141.98
Upside: +45.09%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $63.50
Upside: -37.01%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $3.91
Upside: +142.97%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $10.99
Upside: +118.48%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $13.19
Upside: +81.96%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $155.37
Upside: +15.85%
Recursion Pharmaceuticals
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.89
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $19.79
Upside: +162.76%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $2.55
Upside: +292.16%